

Non-invasive determination of fetal *RHD* status from gestation week 10

Devyser RHD is a CE-IVD test kit used by clinical labs to determine fetal *RHD* status from maternal plasma as early as gestation week 10. Devyser's unique single exon design significantly simplifies your laboratory workflow and analysis. It also enables you to increase throughput and shorten turnaround times.

Simplified testing with high sensitivity

A single exon analysis (exon 4) allows non-invasive detection of fetal *RHD* status from gestation week 10. The assay design simplifies laboratory work, automation and analysis.

Quick start and cost control

All required PCR reagents are included in Devyser's kit. You can get started immediately and have complete control of your costs.

CE-IVD validated workflow

Standardised and validated routine workflow according to the European Regulations and guidelines.

“The single-exon design results in high sensitivity and simple response algorithms.”

Dr. Agneta Wikman, M.D. Associate Prof.
Karolinska University Hospital, Stockholm, Sweden


Workflow

Devyser RHD assay setup




Mix DNA extracted from maternal plasma with kit components

Real-time PCR run



Clinical samples are run and amplification data displayed in real time

Data analysis



Analysis of raw data and determination of fetal *RHD* status

Key features and benefits of Devyser RHD

- | | | |
|---|---|---|
| <ul style="list-style-type: none"> ■ Testing from gestation week 10 ■ Sensitive and specific <i>RHD</i> determination ■ Single exon design ■ Easy to automate ■ Use of maternal plasma |  | <ul style="list-style-type: none"> ■ Stratify your patients early ■ Treat only the <i>RHD</i>-negative mothers at risk ■ Run fewer reactions per sample ■ Reduce risk for errors with streamlined workflow ■ Non-invasive test |
|---|---|---|

Clinical performance

≥99.7%


Diagnostic sensitivity

≥99.5%

Diagnostic specificity

≥99.7%

Correlation to Rhesus serology of the newborn



Discover our Expert Review

Fetal *RHD* Screening in Clinical Routine - Experiences and Considerations

This paper explores an approach which uses non-invasive prenatal testing to determine the fetal *RHD* status, allowing targeted administration of antenatal anti-D prophylaxis only to those who will benefit from it.

Learn more about the current strategies of fetal *RHD* and the experiences and considerations surrounding planning a fetal *RHD* screening program.

Learn more at devyser.com/rhd

Devyser. Results for life.

Devyser is specialized in the development, manufacture and sales of diagnostic kits for standardised genetic testing. Devyser's product development focuses on simplifying and streamlining complex testing processes to improve throughput, reduce hands-on time and produce accurate and trusted results.



CONTACT

Instrumentvägen 19
SE-12653 Hägersten, Sweden
Tel: +46-(0)8-562 158 50
Web: www.devyser.com
Email: info@devyser.com

Please check regulatory status in your country.

Distributed by Abacus dx

1800 ABACUS (AUS) 0800 222 170 (NZ) | info@abacusdx.com | www.abacusdx.com

abacus dx